Heart transplantation cases
| Case | Type of cancer | Allograft outcome | Checkpoint inhibitor | Year from tx to ICI | IS regimen | Cancer response | Interval between IS reduction and ICI initiation | ICI to rejection time |
|---|---|---|---|---|---|---|---|---|
| Daud et al. (2020) [82] | Melanoma | Rejected | Pembrolizumab | 18 | Tac+azathioprine | NA | NA | Within 3 mo |
| LUAC | Rejected | Pembrolizumab | 16 | CYA, MMF, everolimus/sirolimus, Pred | NA | NA | Within 3 mo | |
| Melanoma | Rejected | Nivolumab | 24 | CYA, MMF, Pred | NA | NA | Within 3 mo | |
| Melanoma | No rejection | Pembrolizumab | 19 | Tac | NA | NA | ||
| Grant et al. (2018) [83] | Melanoma | No rejection | Pembrolizumab | 8 | Tac+MMF | PD | NA | |
| Kittai et al. (2017) [30] | LUSC | No rejection | Nivolumab | 10 | CYA+MMF+Pred → CYA+MMF | SD | NA | |
| Owonikoko et al. (2017) [84] | cSCC | Rejected | Nivolumab | 19 | Tac+sirolimus+Pred → Tac+Pred | NA | NA | 5 day |
| Gastman et al. (2016) [85] | Melanoma | No rejection | Ipilimumab×4 | 15 | Tac+MMF+Pred → Tac+Pred | SD | NA | |
| Qin et al. (2015) [86] | Melanoma | No rejection | Ipilimumab×4 | 12 | Tac | PD | NA |
tx, transplantation; ICI, immune checkpoint inhibitor; IS, immunosuppressant; Tac, tacrolimus; NA, not applicable; LUAC, lung adenocarcinoma; CYA, cyclosporin A; MMF, mycophenolate mofetil; Pred, prednisone; PD, progressive disease; LUSC, lung squamous cell carcinoma; SD, stable disease; cSCC, cutaneous squamous cell carcinoma.